Fate Therapeutics
FATE
159 hedge funds and large institutions have $357M invested in Fate Therapeutics in 2023 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 41 increasing their positions, 60 reducing their positions, and 37 closing their positions.
153% more call options, than puts
Call options by funds: $101K | Put options by funds: $40K
76% more capital invested
Capital invested by funds: $203M → $357M (+$154M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.02% less ownership
Funds ownership: 96.88% → 96.86% (-0.02%)
6% less funds holding
Funds holding: 170 → 159 (-11)
24% less first-time investments, than exits
New positions opened: 28 | Existing positions closed: 37
32% less repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 60
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$8.06M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$4.01M |
| 3 |
IHAM
Integral Health Asset Management
New York
|
+$2.12M |
| 4 |
Citigroup
New York
|
+$1.97M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$1.53M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.81M |
| 2 |
BlackRock
New York
|
-$3M |
| 3 |
Millennium Management
New York
|
-$2.76M |
| 4 |
D.E. Shaw & Co
New York
|
-$2.67M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$2.18M |
FATE Hedge Fund Activity: Q4 2023 in Review
159 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q4 2023, worth a combined $357M — up 76% from $203M a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of FATE and 28 opened new positions — a net loss of 9 holders — while 60 trimmed existing stakes and 41 added.
The largest buyer was Point72 Asset Management, adding an estimated $8.06M. The largest seller was Vanguard Group, cutting an estimated $3.81M.
- 159 institutional investors held Fate Therapeutics (FATE) as of Q4 2023, down from 170 in Q3 2023.
- Funds reported $357M of Fate Therapeutics stock for Q4 2023, up 76% quarter-over-quarter.
- 28 funds opened new Fate Therapeutics positions in Q4 2023 and 37 closed out, a net change of -9 holders.
- The largest Fate Therapeutics buyer in Q4 2023 was Point72 Asset Management, an estimated $8.06M added.
- The largest Fate Therapeutics seller in Q4 2023 was Vanguard Group, an estimated $3.81M sold.
Based on aggregated 13F filings for Q4 2023.